Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02424435 · ClinicalTrials.gov registry record · Early Phase 1
Methylprednisolone Treatment of Friedreich Ataxia
A Early Phase 1 study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT02424435: Completed Early Phase 1 study, sponsored by Children's Hospital of Philadelphia.
NCT02424435 is a Early Phase 1 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 11 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02424435, a Early Phase 1 study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will explore whether methylprednisolone treatment is safe, well-tolerated, and beneficial in patients that are diagnosed with Friedreich Ataxia (FRDA). The study will also explore if methylprednisolone has any effects on biomarkers associated with FRDA. All subjects in the study will receive the same steroid treatment.
Primary Outcome
The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The subject is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible. The time is calculated from the initiation of the instruction to start and ends when the subject has reached the 25-foot mark. The task is immediately administered again by having the subject walk back the same distance. Subjects may use assistive devices when doing thi
Interventions
- DRUG Methylprednisolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-04 |
| Phase | Early Phase 1 |
What the finished NCT02424435 record still lists
NCT02424435 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which Methylprednisolone is the first listed.
NCT02424435 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02424435 about?
NCT02424435 is a clinical study titled "Methylprednisolone Treatment of Friedreich Ataxia". This study will explore whether methylprednisolone treatment is safe, well-tolerated, and beneficial in patients that are diagnosed with Friedreich Ataxia (FRDA). The study will also explore if methylprednisolone has any effects on biomarkers associated with FRDA. All subjects in the study will rece...
What is the current status of trial NCT02424435?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2015-06. Estimated completion is 2018-04.
What interventions are being tested in trial NCT02424435?
The interventions under investigation include: Methylprednisolone (DRUG).
Who is sponsoring clinical trial NCT02424435?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02424435's enrollment target sits among peer trials
11 1601st of 2000 higher than 373 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia